Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Merck, Pfizer, AbbVie, Sanofi and Glaxo

Read MoreHide Full Article

For Immediate Release

Chicago, IL – May 6, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Merck (MRK - Free Report) , Pfizer (PFE - Free Report) , AbbVie (ABBV - Free Report) , Sanofi (SNY - Free Report) and Glaxo (GSK - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Pharma Stock Roundup: MRK, LLY, PFE & More

 This week was a relatively busy one for the pharma sector, marked by earnings of bigwigs like Merck and Pfizer. Meanwhile, the European Commission granted approval to AbbVie’s new plaque psoriasis drug Skyrizi (risankizumab) and Sanofi/Lexicon Pharmaceuticals’ dual SGLT1 and SGLT2 inhibitor, Zynquista (sotagliflozin). The Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended marketing approval for several drugs.

Recap of the Week’s Most Important Stories

Q1 Earnings Update: Pfizer, Glaxo and Merck beat estimates for first-quarter earnings and sales. Pfizer raised the mid-point of its earnings expectations for 2019 by a penny and confirmed its previous outlook for full-year sales. Merck raised its expectations for both earnings and sales for the year while Glaxo maintained its previous earnings guidance for 2019.

EU Approval to Sanofi & AbbVie Drugs: The European Commission granted approval to AbbVie’s Skyrizi (risankizumab) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Skyrizi was approved in the United States in late April and is expected to be launched this month. It was approved in Japan in March.

Lexicon Pharmaceuticals and partner Sanofi announced that the European Commission granted approval to their dual SGLT1 and SGLT2 inhibitor, Zynquista (sotagliflozin), in combination with insulin, for the treatment of type I diabetes in adult patients. In March, the FDA had issued a complete response letter (“CRL”) to the new drug application (“NDA”) seeking approval for Zynquista.

CHMP Gives Positive Opinion to Several Drugs: AstraZeneca/Merck’s PARP inhibitor Lynparza gained a positive CHMP opinion, recommending expanded approval for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer. It is already approved in the United States for the indication. The CHMP also gave nod to Novo Nordisk’s Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A. The drug was approved by the FDA in February this year. Glaxo also gained positive CHMP opinion for its once-daily, single-tablet two-drug regimen (2DR), Dovato for the treatment of newly-diagnosed adults with HIV-1 infection. Dovato is a fixed-dose combination of Tivicay (dolutegravir - 50 mg) in combination with lamivudine (300 mg) and was approved by the FDA last month.  Pfizer’s new PARP inhibitor, Talzenna also gained a positive opinion from the CHMP for inherited (germline) BRCA-mutated advanced breast cancer.

The final decision by the European Union on these products is expected in the coming months.

Glaxo/J&J File NDA for Long-Acting Two-Drug HIV Regimen: Glaxo’s HIV subsidiary, ViiV Healthcare and partner J&J filed a NDA looking for approval of long-acting, two-drug regimen of ViiV Healthcare’s cabotegravir and Janssen’s Edurant (rilpivirine). The companies are seeking approval for the two-drug monthly regimen for the treatment of HIV-1-infected adults who had maintained viral suppression and who are not resistant to cabotegravir or rilpivirine. The approval was based on data from the phase III ATLAS study, which showed that the two-drug regimen, injected once a month, had similar efficacy to a standard of care, daily, oral three-drug regimen at week 48.

Glaxo and its partner Innoviva’s phase III study (CAPTAIN) evaluating their triple combination once-daily single inhaler Trelegy Ellipta versus Relvar/Breo Ellipta for a new indication -uncontrolled asthma - met the primary endpoint. Data from the study showed that treatment with Trelegy Ellipta led to statistically significant improvement in lung function in such patients, thereby meeting the study’s primary endpoint. At present, Trelegy Ellipta is approved to treat chronic obstructive pulmonary disease.

Bayer Gets FDA’s Priority Review for Prostate Cancer Candidate: Bayer’s new drug application looking for approval of its prostate cancer candidate, darolutamide was accepted and granted priority review by the FDA. In February 2019, Bayer completed the rolling submission of the NDA for darolutamide to the FDA. The submission is based on data from the phase III ARAMIS study in men with non-metastatic castration-resistant prostate cancer (nmCRPC). Regulatory applications are also under review in Europe and Japan.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                                   

http://www.zacks.com                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.